Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
36-Week Safety Extension of Oral ELND005 in Agitation and Aggression in Moderate to Severe Alzheimer's Disease
2012-005524-15Phase 2Completed
- Sponsor
- Elan
- Start
- Apr 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of scyllo-inositol in Alzheimer's disease (AD), agitation and Aggression (not a disease; see rationale), sponsored by Elan. Primary endpoint: Safety endpoints. Started Apr 2013; status: completed.
02
Drugs
scyllo-inositol
03
Conditions
Alzheimer's disease (AD)agitationAggression (not a disease; see rationale)
Beyond the preview
Go deeper on 2012-005524-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-005524-15.